Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Rating of “Buy” by Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and three have given a strong buy recommendation to the company.

A number of brokerages recently issued reports on BAYRY. Jefferies Financial Group raised Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Finally, Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th.

Bayer Aktiengesellschaft Price Performance

BAYRY stock opened at $9.88 on Wednesday. The stock has a market cap of $38.83 billion, a PE ratio of -15.44, a P/E/G ratio of 3.24 and a beta of 0.59. Bayer Aktiengesellschaft has a 12 month low of $7.03 and a 12 month high of $14.85. The company has a 50-day moving average price of $11.22 and a 200 day moving average price of $11.25. The company has a current ratio of 1.01, a quick ratio of 0.63 and a debt-to-equity ratio of 1.22.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. The business had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities research analysts anticipate that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.